Hormone Replacement Therapy and Risk of Severe Asthma Exacerbation in Perimenopausal and Postmenopausal Women: 17-Year National Cohort Study

Заместительная гормональная терапия и риск тяжелого обострения астмы у женщин в перименопаузе и постменопаузе: 17-летнее национальное когортное исследование
Bright I. Nwaru, Syed Ahmar Shah, Holly Tibble, Rebecca Pillinger, Susannah McLean, Dermot Ryan, Hilary Critchley, Catherine M. Hawrylowicz, Colin R Simpson, Ireneous N Soyiri, Francis Appiagyei, David Price, Aziz Sheikh
2021-03-09

hormone replacement therapymultilevel Poisson regressionnational cohort studyperimenopausal and postmenopausal womensevere asthma exacerbation
Background The impact of hormone replacement therapy (HRT) on clinical outcomes in menopausal women is uncertain. Objective To investigate the association between use of HRT and severe asthma exacerbation in perimenopausal and postmenopausal women with asthma. Methods We used the Optimum Patient Care Research Database, a population-based longitudinal primary care database in the United Kingdom, to construct a 17-year (January 1, 2000, to December 31, 2016) cohort of perimenopausal and postmenopausal (46-70 years, N = 31,656) women. We defined use of HRT, its subtypes, and duration of HRT use. Severe asthma exacerbation was defined as an asthma-related hospitalization, emergency department visits due to asthma, and/or prescription of oral corticosteroids. Analyses were undertaken using multilevel mixed-effects Poisson regression. Results At baseline, 22% of women were using any HRT, 11% combined HRT, and 11% estrogen-only HRT. Previous, but not current, use of any (incidence rate ratio [IRR]: 1.24, 95% confidence interval [CI]: 1.22-1.26), combined (IRR: 1.28, 95% CI: 1.25-1.31), and estrogen-only HRT (IRR: 1.18, 95% CI: 1.14-1.21), and longer duration (1-2 years: IRR: 1.16, 95% CI: 1.13-1.19; 3-4 years: IRR: 1.43, 95% CI: 1.38-1.48; 5+ years: IRR: 1.32, 95% CI: 1.28-1.36) of HRT use were associated with increased risk of severe asthma exacerbation compared with nonuse. The risk estimates were greater among lean women (body mass index [BMI] <25 kg/m 2 ) than among heavier women (BMI 25-29.9 kg/m 2 and ≥30 kg/m 2 ) and higher among smokers than nonsmokers. Conclusion Use of HRT and subtypes, particularly previous, but not current, use and use for more than 2 years, is associated with an increased risk of severe asthma exacerbation in perimenopausal/postmenopausal women with established asthma. Lean women and smokers are at greater risk than heavier women and nonsmokers, respectively.
1
A 17-year UK cohort study followed 31,656 perimenopausal and postmenopausal women with asthma to assess HRT and severe exacerbations.
2
Associations were stronger among lean women and smokers than among heavier women and nonsmokers.
3
HRT use for more than 2 years was associated with higher exacerbation risk, peaking at 3-4 years (IRR 1.43, 95% CI 1.38-1.48).
4
Previous combined HRT and estrogen-only HRT were associated with increased exacerbation risks (IRRs 1.28 and 1.18, respectively).
5
Previous, but not current, use of any HRT was associated with increased severe asthma exacerbation risk (IRR 1.24, 95% CI 1.22-1.26).

Perimenopausal and postmenopausal women with established asthma using hormone replacement therapy

The association of HRT use, subtype, duration, BMI, and smoking status with the risk of severe asthma exacerbation

Publication Details
Publication Date
2021-03-09
Journal
Publisher
ISSN
Cited by
29
Access Type
Author Information
Authors
Bright I. Nwaru
Syed Ahmar Shah
Holly Tibble
Rebecca Pillinger
Susannah McLean
Dermot Ryan
Hilary Critchley
Catherine M. Hawrylowicz
Colin R Simpson
Ireneous N Soyiri
Francis Appiagyei
David Price
Aziz Sheikh
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%